You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 277 No. 13, April 2, 1997 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Grand Rounds at the Clinical Center of the National Institutes of Health
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

New Approaches to the Treatment of Congenital Adrenal Hyperplasia

Deborah P. Merke, MD; Gordon B. Cutler, Jr, MD

JAMA. 1997;277(13):1073-1076.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

SELECTED CASE

A female patient, now 7 years 6 months old, had developed pubic hair at approximately 2 years of age. At 4 years of age she developed acne and was taken to a pediatrician. Findings on physical examination included a height of 109 cm (95th percentile), a weight of 17 kg (75th percentile), Tanner I breasts, Tanner II pubic hair, clitoromegaly (clitoral index of 49 mm2; normal,1 <35 mm2), posterior labial fusion, and acne. The bone age was advanced (6 years 10 months). Serum levels were as follows: 17-hydroxyprogesterone, 380 nmol/L (normal, <2.7 nmol/L); androstenedione, 11.2 nmol/L (normal, <1.7 nmol/L); testosterone, 1.4 nmol/L (0.40 ng/mL) (normal, <1.0 nmol/L [<0.29 ng/mL]); dehydroepiandrosterone, 7.6 nmol/L (normal, 0.6-2.1 nmol/L); and upright renin, 2.9 µg/L per hour (normal, 0.1-6.5 µg/L per hour). She was diagnosed as having congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency and began treatment with hydrocortisone . . . [Full Text PDF of this Article]


Author Affiliations

From the Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Md. Drs Merke and Cutler are commissioned officers in the US Public Health Service.


Footnotes

Reprints: Deborah P. Merke, MD, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bldg 10, Room 10N262, 10 Center Dr MSC 1862, Bethesda, MD 20892-1862.

Grand Rounds at the Clinical Center of the National Institutes of Health section editors: John I. Gallin, MD, the Warren Grant Magnuson Clinical Center of the National Institutes of Health, Bethesda, Md; David S. Cooper, MD, Contributing Editor, JAMA.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.